Abstract | PURPOSE: METHODS: Plasma and cerebrospinal fluid (CSF) samples collected from Ph+ ALL patients treated with dasatinib were analyzed by using an LC-MS/MS assay. FINDINGS: Orally administered dasatinib 100 mg once daily was well absorbed by the patient but penetrated poorly into the CSF. The use of a higher drug dosage (140 mg/d) may increase systemic drug exposure and enhance the penetration of dasatinib into the CSF. IMPLICATIONS: Based on this study, the use of a higher dosage of dasatinib (140 mg/d) is recommended in patients at high risk of CNS relapse or patients who need treatment for CNS leukemia. ClinicalTrials.gov identifier: NCT02523976.
|
Authors | Xiaoyuan Gong, Le Li, Hui Wei, Bingcheng Liu, Chunlin Zhou, Guangji Zhang, Kaiqi Liu, Dong Lin, Benfa Gong, Shuning Wei, Yan Li, Yingchang Mi, Ying Wang, Jianxiang Wang |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 43
Issue 7
Pg. 1265-1271.e1
(07 2021)
ISSN: 1879-114X [Electronic] United States |
PMID | 34120773
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Inc. All rights reserved. |
Chemical References |
- Protein Kinase Inhibitors
- Dasatinib
|
Topics |
- Blood-Brain Barrier
- Chromatography, Liquid
- Dasatinib
- Humans
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy)
- Protein Kinase Inhibitors
- Tandem Mass Spectrometry
|